Form 4: Neurocrine CFO's RSU Vesting and Tax Withholding

Neurocrine Biosciences' CFO, Matt Abernethy, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NBIX), reported changes in his beneficial ownership of common stock.
• On January 31, 2026, 2,437 Restricted Stock Units (RSUs) vested and converted into common stock.
• Concurrently, 1,368 shares were withheld by Neurocrine Biosciences, Inc. at a price of $136.06 per share to satisfy tax withholding requirements related to the RSU vesting.
• No shares were sold by Mr. Abernethy in the open market; the disposition was solely for tax purposes.
• Following these transactions, Mr. Abernethy's direct beneficial ownership of common stock decreased from 38,465 shares to 37,097 shares.
• The reported beneficial ownership includes 218 shares purchased on August 29, 2025, through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the normal course of executive compensation and RSU vesting, which is a planned and expected occurrence.

Positives

• The vesting of 2,437 Restricted Stock Units indicates continued long-term incentive compensation for the Chief Financial Officer, aligning executive interests with shareholder value.
• The transaction is a standard RSU vesting event, demonstrating the company's established executive compensation structure.

Negatives

• A reduction in direct beneficial ownership by 1,368 shares due to tax withholding, while not a sale, decreases the insider's direct stake in the company.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are routine events in executive compensation across the biotechnology and pharmaceutical industries. This filing reflects a standard mechanism for long-term incentive plans, aligning executive interests with shareholder value creation over time.

Stakeholder Impact

• Shareholders: The filing indicates a routine executive compensation event, which is generally expected and does not suggest any immediate material impact on company operations or strategy.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a broader employee benefit program.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving RSU vesting and tax withholding, which is a standard part of executive compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Matt Abernethy, CFO, Stock Ownership